Novo Nordisk A/S (NVO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
$39.14 +2.22% NYSE • Public Delayed / 60s Snapshot
Novo Nordisk A/S (NVO) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C+ • HOLD / WATCH
Cap $173.31B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($18.7M)
40% PutsMax Pain: $38.00
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months
How NVO Turns Every Dollar of Sales Into Real Bottom-Line Profit
Free Cash Flow:$3.83B (15.8% FCF Margin)
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring NVO)
- ✓Live walkthrough of NVO's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
NVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.26%📐 HORIZONTAL RANGE
2026-10-30O $39.61H $40.10L $39.54C $40.00VOL 15.25M
RES: $58.40SUP: $34.06SMA50: $41.23SMA200: $44.19
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NVO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
NVO → ISRG Confirmed Filing
Intuitive Surgical explicitly disclosed in its Form 10-K that US bariatric surgery procedure volumes on da Vinci robotic systems slowed as patients trialed GLP-1 weight-loss drugs prior to surgery.
DHR → NVO Analyst Hypothesis
Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
NVO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Novo Nordisk A/S (NVO)?
In Trailing 12 Months, NVO converted $24.3B of revenue into a 41% gross margin, 13.9% operating margin, and $3.8B in free cash flow (15.8% FCF margin).